Septerna (Nasdaq: SEPN) announced an inducement stock option grant to Chief Legal Officer Mark A. Wilson on February 6, 2026. The non-qualified option covers 165,000 shares with an exercise price of $25.41, equal to the closing price on February 6, 2026, and vests over four years.
The option vests 25% after one year, with the remaining 75% vesting monthly over 36 months, subject to continued employment and plan terms.
Loading...
Loading translation...
Positive
None.
Negative
None.
Key Figures
Option grant size:165,000 sharesExercise price:$25.41 per shareInitial vesting portion:25%+2 more
5 metrics
Option grant size165,000 sharesNon-qualified stock option under 2026 Inducement Plan for Chief Legal Officer
Exercise price$25.41 per shareEqual to closing share price on February 6, 2026
Initial vesting portion25%Vests on one-year anniversary of vesting commencement date
Remaining vesting period36 monthsRemaining 75% vests in equal monthly installments
Vesting term4 yearsTotal vesting period for the stock option grant
Market Reality Check
Price:$26.70Vol:Volume 365,103 is at 1.18...
normal vol
$26.70Last Close
VolumeVolume 365,103 is at 1.18x the 20-day average of 310,685, indicating modestly elevated trading activity pre-announcement.normal
TechnicalShares at $26.59 are trading above the 200-day moving average of $17.29 and sit 12.82% below the 52-week high of $30.50.
Peers on Argus
SEPN gained 4.64% while peers were mixed: KROS up 0.23%, SVRA down 1.32%, TERN d...
SEPN gained 4.64% while peers were mixed: KROS up 0.23%, SVRA down 1.32%, TERN down 3.65%, TYRA down 1.71%, and ANAB flat. This pattern points to a stock-specific move rather than a coordinated biotechnology sector rotation.
Outlined participation in November 2025 investor conference fireside chats.
Pattern Detected
Recent news flow shows mixed price reactions, with leadership and earnings updates sometimes followed by short-term declines, while conference-related announcements have produced relatively modest, directionally varied moves.
Recent Company History
Over the last several months, Septerna has reported leadership expansion, investor conference participation, and a profitable Q3 2025 with collaboration-driven revenue. Earnings on Nov 10, 2025 and the appointment of a Chief Legal Officer on Jan 8, 2026 were followed by modest negative price moves, while conference announcements in late 2025 saw smaller, mixed reactions. Today’s inducement option grant for the new Chief Legal Officer fits into this leadership build-out and incentive alignment theme.
Market Pulse Summary
This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant of 165,000 non-qualifie...
Analysis
This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant of 165,000 non-qualified stock options at an exercise price of $25.41, vesting over 4 years. It follows the earlier appointment of the Chief Legal Officer, reinforcing leadership expansion and equity-based incentives. Investors may track how such awards align management with shareholder outcomes alongside prior milestones, including profitable Q3 2025 results and ongoing clinical development progress.
Key Terms
g protein-coupled receptor, gpcr, non-qualified stock option, nasdaq listing rule 5635(c)(4), +3 more
7 terms
g protein-coupled receptormedical
"a new era of G protein-coupled receptor (GPCR) drug discovery"
A G protein-coupled receptor is a protein on a cell’s surface that acts like an antenna: it detects signals such as hormones, neurotransmitters or drugs outside the cell and passes that message inside to change cell behavior. Investors care because roughly a third of marketed medicines act on these receptors, so a company’s success in targeting or modulating a specific receptor can determine the value of drug candidates, regulatory risk, and future revenue potential.
gpcrmedical
"a new era of G protein-coupled receptor (GPCR) drug discovery"
G protein-coupled receptors (GPCRs) are a large family of proteins on cell surfaces that act like locks sensing chemical signals — when the right key binds, they trigger internal cell responses. They matter to investors because GPCRs are the target of many marketed drugs and experimental therapies; success or failure in developing a GPCR-targeting drug can change a company’s revenue prospects, clinical progress, and licensing value, much like winning control of a widely used distribution channel.
non-qualified stock optionfinancial
"consisting of a non-qualified stock option to purchase 165,000 shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"The stock option has an exercise price of $25.41 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"will vest over four years, with 25% of the underlying shares vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement planregulatory
"under the Company’s 2026 Inducement Plan"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026, the company’s Board of Directors granted an inducement award to Mark A. Wilson, Septerna’s Chief Legal Officer, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company’s 2026 Inducement Plan. The award was granted as an inducement material to Mr. Wilson’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of $25.41 per share, equal to Septerna’s closing share price on February 6, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining 75% vesting thereafter in equal monthly installments over 36 months, subject to Mr. Wilson’s continuous employment through the applicable vesting dates. The stock option is subject to the terms and conditions of the Company’s 2026 Inducement Plan and the applicable stock option agreement.
About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
What did Septerna (SEPN) grant Mark A. Wilson on February 6, 2026?
Septerna granted Mark A. Wilson a non-qualified stock option to purchase 165,000 shares. According to the company, the option carries an exercise price of $25.41 and vests over four years with standard continued-employment conditions.
What is the exercise price and how was it determined for the SEPN inducement option?
The exercise price for the SEPN option is $25.41 per share, equal to the closing share price on February 6, 2026. According to the company, the price reflects the market close on the grant date and follows Nasdaq inducement practices.
What is the vesting schedule for the SEPN inducement grant to the chief legal officer?
The SEPN option vests over four years: 25% at one year, then 75% monthly over 36 months. According to the company, vesting is conditional on Mr. Wilson's continuous employment through each applicable vesting date.
Under what rule was the Septerna grant to Mark A. Wilson approved and why does it matter?
The grant was made under Nasdaq Listing Rule 5635(c)(4) as an inducement award. According to the company, this rule permits stock-based inducements for newly hired executives as a marketplace compliance mechanism.
How can investors find the terms governing the SEPN 2026 inducement option?
The option is subject to the Company’s 2026 Inducement Plan and the stock option agreement. According to the company, investors should consult those documents for full terms, restrictions, and any additional conditions.
